Structure–activity and structure–metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

Jon H. Condra, William A. Schleif, O M Blahy et al. · Nature · 1995 · 979 citations

Life Sciences, Infectious Diseases, Molecular Biology +16

[17] The kinetics of reversible tight-binding inhibition

Jeffrey W. Williams, John F. Morrison · Methods in enzymology on CD-ROM/Methods in enzymology · 1979 · 692 citations

Life Sciences, Biochemistry, Pharmacology +10

New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity

O. S. Weislow, Rebecca Kiser, Donald L. Fine et al. · JNCI Journal of the National Cancer Institute · 1989 · 691 citations

Public Health, Infectious Diseases, Hiv Control +7

Viracept (Nelfinavir Mesylate, AG1343):  A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease

Stephen W. Kaldor, Vincent J. Kalish, Jay F. Davies et al. · Journal of Medicinal Chemistry · 1997 · 620 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

Dale J. Kempf, Kennan C. Marsh, Gondi Kumar et al. · Antimicrobial Agents and Chemotherapy · 1997 · 420 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17